Answers are grounded in this paper and cite their sources.
Adipose-derived stem cells (ASCs) are being studied for tissue repair because they can affect immune and vascular cells. Their effects, however, depend on the product, tissue, cell state, and outcome being measured. This review examines how ASCs interact with macrophages, endothelial cells, and other stromal cells. We separate direct experiments from observations in human or animal tissues and from relationships inferred by computational analysis. In mouse studies, ASC-derived interleukin-1 receptor antagonist has been linked to changes in macrophage phenotype. ASC preconditioning has also increased cyclooxygenase-2 (COX-2) expression and prostaglandin E2 (PGE2) secretion. These molecular changes alone do not show that macrophages resolved inflammation. Other studies report vascular responses and better wound repair after treatment with ASC-derived factors or extracellular vesicles. They have not established which molecular pathways cause clinical benefit in ASC-treated human wounds. Spatial analysis may help identify candidate immune–vascular niches, and graph-based artificial intelligence may test whether their cell organization adds information beyond cell numbers and clinical variables. These proposed niches remain research hypotheses, not established features of ASC-treated human wounds. Clinical translation will require a defined ASC product, measurable changes in wound-cell function, adequate tissue perfusion, durable closure, and reproducible safety.
No takes yet. Share an insight, caveat, or question.
Weng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: